ACADIA Pharmaceuticals Inc (ACAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has a cash flow conversion efficiency ratio of 0.103x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($134.76 Million) by net assets ($1.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of ACADIA Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
ACADIA Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ACADIA Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ACADIA Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of ACADIA Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ExlService Holdings Inc
NASDAQ:EXLS
|
0.002x |
|
Premier Energies Limited
NSE:PREMIERENE
|
0.144x |
|
Marex Group plc Ordinary Shares
NASDAQ:MRX
|
0.375x |
|
SCOR.ADR1/10/EO-78769723
F:SDRB
|
N/A |
|
Mega Or
TA:MGOR
|
0.054x |
|
Hangzhou Lion Electronics Co Ltd
SHG:605358
|
0.020x |
|
Bumrungrad Hospital Public Company Limited
BK:BH-R
|
0.057x |
|
Aneka Tambang Persero Tbk
JK:ANTM
|
0.062x |
Annual Cash Flow Conversion Efficiency for ACADIA Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ACADIA Pharmaceuticals Inc from 2002 to 2025. View ACAD stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.23 Billion | $109.84 Million | 0.089x | -58.42% |
| 2024-12-31 | $732.79 Million | $157.72 Million | 0.215x | +456.38% |
| 2023-12-31 | $431.75 Million | $16.70 Million | 0.039x | +113.58% |
| 2022-12-31 | $400.41 Million | $-114.03 Million | -0.285x | -22.59% |
| 2021-12-31 | $540.89 Million | $-125.66 Million | -0.232x | -6.98% |
| 2020-12-31 | $627.01 Million | $-136.17 Million | -0.217x | -0.46% |
| 2019-12-31 | $699.13 Million | $-151.13 Million | -0.216x | +38.16% |
| 2018-12-31 | $479.08 Million | $-167.47 Million | -0.350x | +46.20% |
| 2017-12-31 | $335.29 Million | $-217.86 Million | -0.650x | -60.09% |
| 2016-12-31 | $518.41 Million | $-210.41 Million | -0.406x | +33.43% |
| 2015-12-31 | $199.76 Million | $-121.80 Million | -0.610x | -184.03% |
| 2014-12-31 | $309.49 Million | $-66.43 Million | -0.215x | -23.06% |
| 2013-12-31 | $182.13 Million | $-31.77 Million | -0.174x | +31.48% |
| 2012-12-31 | $84.98 Million | $-21.63 Million | -0.255x | +70.11% |
| 2011-12-31 | $23.36 Million | $-19.90 Million | -0.852x | -136.24% |
| 2010-12-31 | $29.69 Million | $-10.70 Million | -0.361x | +68.18% |
| 2009-12-31 | $12.11 Million | $-13.73 Million | -1.133x | +7.43% |
| 2008-12-31 | $52.99 Million | $-64.87 Million | -1.224x | -153.92% |
| 2007-12-31 | $113.93 Million | $-54.93 Million | -0.482x | +21.83% |
| 2006-12-31 | $67.16 Million | $-41.42 Million | -0.617x | -19.83% |
| 2005-12-31 | $39.37 Million | $-20.26 Million | -0.515x | +23.70% |
| 2004-12-31 | $30.68 Million | $-20.69 Million | -0.674x | -461.90% |
| 2003-12-31 | $-52.67 Million | $-9.82 Million | 0.186x | -19.17% |
| 2002-12-31 | $-40.09 Million | $-9.24 Million | 0.231x | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more